| Title |
Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, April 2021
|
| DOI | 10.2147/ceor.s302097 |
| Pubmed ID | |
| Authors |
Maria Mareque, Pau Montesinos, Patricia Font, José María Guinea, Adolfo de la Fuente, Javier Soto, Itziar Oyagüez, James Brockbank, Tamara Iglesias, Julia Llinares, Jorge Sierra |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 11 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 18% |
| Student > Bachelor | 2 | 18% |
| Other | 1 | 9% |
| Professor > Associate Professor | 1 | 9% |
| Student > Postgraduate | 1 | 9% |
| Other | 0 | 0% |
| Unknown | 4 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Economics, Econometrics and Finance | 3 | 27% |
| Business, Management and Accounting | 1 | 9% |
| Biochemistry, Genetics and Molecular Biology | 1 | 9% |
| Nursing and Health Professions | 1 | 9% |
| Social Sciences | 1 | 9% |
| Other | 0 | 0% |
| Unknown | 4 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2021.
All research outputs
#20,015,055
of 25,462,162 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#395
of 525 outputs
Outputs of similar age
#329,298
of 454,089 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#12
of 17 outputs
Altmetric has tracked 25,462,162 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,089 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.